CALI BIOTPAR Calidi Biotherapeutics, Inc. announced the appointment of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. This addition increases the board?s membership to eight. Dr. Gilbert most recently served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024.
Under Dr. Gilbert?s leadership, his team of laboratory and clinical investigators conducted research that advanced science in the brain tumor field. He developed robust clinical trials based on strong preclinical findings, improving patient outcomes through innovative combination treatments and precision medicine approaches. Before joining NIH, Dr. Gilbert practiced under another Medical Advisory Board member, world-renowned oncologist Dr. Alfred Yung, at MD Anderson in Houston from 1990 to 2014.
Prior to that, Dr. Gilbert worked at UPMC in Pittsburgh, Emory University in Atlanta, and Johns Hopkins in Baltimore. Dr. Gilbert received his Doctor of Medicine degree from Johns Hopkins University in 1982 (Alpha Omega Alpha) and completed residencies in internal medicine and neurology, as well as a neuro-oncology fellowship at Johns Hopkins. Other members of the Calidi Biotherapeutics Medical Advisory Board include W.K. Alfred Yung, MD (MD Anderson); Karen Aboody, MD (City of Hope), Santosh Kesari, MD/PhD (Saint John?s Cancer Institute); Matt Lesniak, MD (Northwestern University); Ewa Carrier, MD (FibroGen); Dmitriy Zamarin, MD/PhD (Mount Sinai); Ashok Srivastava MD/PhD (CliniFomatrix).
